Elite Pharmaceuticals Inc
OTC:ELTP
Net Margin
Elite Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Elite Pharmaceuticals Inc
OTC:ELTP
|
792.7m USD |
-26%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
13%
|
Elite Pharmaceuticals Inc
Glance View
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Elite Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -25.7%.
You don't have any saved screeners yet